Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
October 04, 2018 - N°20180280328

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, ...
Metabolomic signature of diagnosis and disease progression in non-alcoholic fatty liver disease (nafld)
One Way Liver, S.l.
September 27, 2018 - N°20180275151

The present invention is directed to a diagnostic method for non-alcoholic fatty liver disease (nafld) and to a method for monitoring the progression of the disease based on the determination of the levels of different metabolites. The invention also provides a method for determining the efficacy of an nafld therapy and a method for identification of compounds suitable for the ...
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
September 27, 2018 - N°20180273955

The invention relates to double stranded ribonucleic acid (dsrnai) agents and compositions targeting the scap gene, as well as methods of inhibiting expression of a scap gene and methods of treating subjects having a scap-associated disorder, such as nonalcoholic fatty liver disease (nafld) or nonalcoholic steatohepatitis (nash), using such dsrnai agents and compositions.. .
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition for prevention, amelioration or treatment of metabolic syndrome
September 20, 2018 - N°20180264020

The mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.. .
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
September 13, 2018 - N°20180259537

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.
Methods for molecular classification of fatty liver by high-throughput protein post-translational modifications
September 13, 2018 - N°20180259515

The present invention is directed towards methods for treating non-alcoholic fatty liver disease (nafld) in a patient and determining prognosis of nafld in a patient.. .
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as ...
September 13, 2018 - N°20180256520

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low ...
Chemical compounds
August 23, 2018 - N°20180237441

The compounds of the invention are inhibitors of perk and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, huntington's disease, creutzfeldt-jakob disease, fatal familial insomnia, gerstmann-sträussler-scheinker ...
Notch inhibition in the treatment and prevention of nonalcoholic fatty liver disease
The Brigham And Women's Hospital
August 16, 2018 - N°20180230207

The present invention is directed to methods of treating or preventing nonalcoholic fatty liver disease by administering agents that inhibit the notch signaling pathway. Antibodies that inhibit the binding of delta like 4 ligand (dll4) to notch receptors may be used for this purpose..
Adiponectin secretion enhancer
Oriental Yeast Co., Ltd.
August 16, 2018 - N°20180228824

The present disclosure provides for the administration of β-nmn, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can he ingested in order to increase the secretion of ...
Treatment and prevention of liver disease associated with parenteral nutrition (pn)
Children's Medical Center Corporation
August 09, 2018 - N°20180221323

The present invention is based on the discovery that parenteral nutrition (pn) induced liver disease, e.g. Fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with pn rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid.
Non-alcoholic fatty liver regulator 14-3-3 protein
Korea University Research And Business Foundation
August 02, 2018 - N°20180214578

The present invention relates to the 14-3-3 protein which is a non-alcoholic fatty liver regulating factor. According to the present invention, two isoform proteins of 14-3-3, i.e., 14-3-3β and 14-3-3γ, are different regulating factors for regulating the transcriptional activity of pparγ2.
5-ht2c receptor agonists and compositions and methods of use
Arena Pharmaceuticals, Inc.
August 02, 2018 - N°20180214455

Provided in some embodiments are compounds of formula a, as defined herein, that modulate the activity of 5-ht2c receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)
Hadasit Medical Research Services And Development Ltd.
July 19, 2018 - N°20180202001

A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting nlgn4 gene product expression level.. .
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
Alnylam Pharmaceuticals, Inc.
July 19, 2018 - N°20180201936

The invention relates to polynucleotide agents targeting a patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such polynucleotide agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.. .
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
July 19, 2018 - N°20180200334

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Method for treating fatty liver
Npo Amami Functional Foods Study Group
July 19, 2018 - N°20180200317

A method of treating fatty liver comprising administering an effective amount of a plant belonging to a genus cirsium to a patient in need of the treatment.. .
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
July 12, 2018 - N°20180193590

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Prevention and treatment of inflammatory conditions
Gri Bio, Inc.
July 12, 2018 - N°20180193368

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ald). More specifically the present embodiments relate to the prevention and treatment of ald through the administration of an retinoic acid receptor (rar) agonist.
Use of zoledronic acid to prepare drug treating fatty liver disease
Nanjing University
July 12, 2018 - N°20180193364

A method for treating fatty liver disease in a patient in need thereof, including a step of administering an effective amount of zoledronic acid. The fatty liver disease includes fatty liver disease caused by foodborne and hereditary factors, in particular non-alcoholic fatty liver.
Fatty acid amides for the prevention and/or treatment of steatohepatitis
FundaciÓ Institut Mar D'investigacions MÈdiques
July 12, 2018 - N°20180193293

The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis ...
Loading